GlassScriptPhysician profile
Melissa Lynn Korb
NPI 1174841480
$11,320.96
in general payments reported to CMS, 2019-2025
10 companies · $88.95 in 2025
The $88.95 reported for 2025 was less than what a typical Thoracic Surgery (Cardiothoracic Vascular Surgery) provider received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $10K · 2022: $799 · 2023: $52.61 · 2024: $305 · 2025: $88.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $446.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,975.81 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $111.04 | 2023-2025 | Keytruda, Lynparza |
| Janssen Biotech, INC. | $51.73 | 2024-2025 | Rybrevant, Erleada |
| Incyte Corporation | $40.31 | 2024 | Jakafi, Monjuvi |
| Array Biopharma INC | $32.91 | 2024 | Mektovi, Braftovi, Lorbrena |
| Ethicon US, LLC | $28.59 | 2021 | |
| Daiichi Sankyo INC. | $28.48 | 2022 | |
| Puma Biotechnology, INC. | $19.93 | 2023 | |
| Medinc of Texas | $17.31 | 2024 | |
| Genentech USA, INC. | $14.85 | 2024 | Tecentriq, Alecensa, Tecentriq Hybreza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Korb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.